Cemiplimab (anti-PD-1)

製品コードA2022 別名: REGN-2810, cemiplimab-rwlc 純度：99.3%

Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫あり
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

文献中Selleckの製品使用例（1）

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99.3% タンパク質濃度： 5 mg/ml 内毒素： <1 EU/mg

99.3

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明	Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
同型	Human IgG4

In Vitro
In Vitro	In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.
細胞実験	Objective: T cell activation bioassays Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 4-6 h Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Objective: T cell activation bioassays Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 72 h Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

In Vivo
In Vivo	Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.
動物試験	Objective: MC38 mouse colon carcinoma Animal Models: adult human PD-1 knock-in mice Formulation: -- Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Objective: pharmacokinetic (PK) study Animal Models: cynomolgus monkeys (Macaca fascicularis) Formulation: -- Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg Administration: i.v. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

参考
https://pubmed.ncbi.nlm.nih.gov/28265006/

参考

https://pubmed.ncbi.nlm.nih.gov/28265006/

製品説明

CAS No.	1801342-60-8
Formulation	PBS buffer. Contains no stabilizers or preservatives
Isotype	Human IgG4
Source	HEK293
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07365839	NOT_YET_RECRUITING	Drug: Arm 1 cemiplimab\|Drug: Arm 2 cemiplimab and fianlimab	Hepatocellular Carcinoma	Virginia Commonwealth University	2026-10-01	PHASE1
NCT07195734	RECRUITING	Drug: Carboplatin\|Drug: Cisplatin\|Drug: Paclitaxel	Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Recurrent Head and Neck Squamous Cell Carcinoma; Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma; Locally Recurrent Laryngeal Squamous Cell Carcinoma; Locally Recurrent Oral Cavity Squamous Cell Carcinoma; Locally Recurrent Oropharyngeal Squamous Cell Carcinoma; Stage II Laryngeal Cancer AJCC v8; Stage II Lip and Oral Cavity Cancer AJCC v8; Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8	National Cancer Institute (NCI)	2026-04-24	PHASE2
NCT07567469	NOT_YET_RECRUITING	Drug: Cemiplimab\|Drug: Cemiplimab+Fianlimab Fixed Dose Combi	High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma	Regeneron Pharmaceuticals	2026-08-31	PHASE1; PHASE2
NCT06794775	RECRUITING	Drug: Nivolumab\|Drug: Nivolumab + Ipilimumab	Malignant Melanoma Stage III	Hildur Helgadottir	2025-07-10	PHASE3
NCT06917573	RECRUITING	Drug: Cemiplimab\|Drug: Carboplatin\|Drug: Paclitaxel	Non Small Cell Lung Cancer Metastatic; Lung Diseases; Stage IV Non-small Cell Lung Cancer; Stage III Non-small Cell Lung Cancer; Respiratory Tract Neoplasms; Thoracic Neoplasms	Fundación GECP	2025-07-29	PHASE2
NCT07346196	NOT_YET_RECRUITING	Drug: Cemiplimab\|Drug: Fianlimab\|Drug: Carboplatin\|Drug: Pac	Squamous Cell Carcinoma	University of Chicago	2027-02-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-25)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須